Base de dados : MEDLINE
Pesquisa : D03.383.710 [Categoria DeCS]
Referências encontradas : 6136 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 614 ir para página                         

  1 / 6136 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29376560
[Au] Autor:Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
[Ad] Endereço:Department of Anaesthesiology and Surgical Intensive Care, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
[Ti] Título:Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
[So] Source:Cochrane Database Syst Rev;1:CD009669, 2018 01 29.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) as complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are life-threatening conditions. While there is a broad body of evidence for the treatment of people with acute coronary syndrome under stable haemodynamic conditions, the treatment strategies for people who become haemodynamically unstable or develop CS remain less clear. We have therefore summarised here the evidence on the treatment of people with CS or LCOS with different inotropic agents and vasodilative drugs. This is the first update of a Cochrane review originally published in 2014. OBJECTIVES: To assess efficacy and safety of cardiac care with positive inotropic agents and vasodilator strategies in people with CS or LCOS due to AMI, HF or cardiac surgery. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase and CPCI-S Web of Science in June 2017. We also searched four registers of ongoing trials and scanned reference lists and contacted experts in the field to obtain further information. No language restrictions were applied. SELECTION CRITERIA: Randomised controlled trials in people with myocardial infarction, heart failure or cardiac surgery complicated by cardiogenic shock or LCOS. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We identified 13 eligible studies with 2001 participants (mean or median age range 58 to 73 years) and two ongoing studies. We categorised studies into eight comparisons, all against cardiac care and additional other active drugs or placebo. These comparisons investigated the efficacy of levosimendan versus dobutamine, enoximone or placebo, epinephrine versus norepinephrine-dobutamine, amrinone versus dobutamine, dopexamine versus dopamine, enoximone versus dopamine and nitric oxide versus placebo.All trials were published in peer-reviewed journals, and analysis was done by the intention-to-treat (ITT) principle. Twelve of 13 trials were small with few included participants. Acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements emerged in five of 13 trials. In general, confidence in the results of analysed studies was reduced due to serious study limitations, very serious imprecision or indirectness. Domains of concern, which show a high risk of more than 50%, include performance bias (blinding of participants and personnel) and bias affecting the quality of evidence on adverse events.Levosimendan may reduce short-term mortality compared to a therapy with dobutamine (RR 0.60, 95% CI 0.37 to 0.95; 6 studies; 1776 participants; low-quality evidence; NNT: 16 (patients with moderate risk), NNT: 5 (patients with CS)). This initial short-term survival benefit with levosimendan vs. dobutamine is not confirmed on long-term follow up. There is uncertainty (due to lack of statistical power) as to the effect of levosimendan compared to therapy with placebo (RR 0.48, 95% CI 0.12 to 1.94; 2 studies; 55 participants, very low-quality evidence) or enoximone (RR 0.50, 95% CI 0.22 to 1.14; 1 study; 32 participants, very low-quality evidence).All comparisons comparing other positive inotropic, inodilative or vasodilative drugs presented uncertainty on their effect on short-term mortality with very low-quality evidence and based on only one RCT. These single studies compared epinephrine with norepinephrine-dobutamine (RR 1.25, 95% CI 0.41 to 3.77; 30 participants), amrinone with dobutamine (RR 0.33, 95% CI 0.04 to 2.85; 30 participants), dopexamine with dopamine (no in-hospital deaths from 70 participants), enoximone with dobutamine (two deaths from 40 participants) and nitric oxide with placebo (one death from three participants). AUTHORS' CONCLUSIONS: Apart from low quality of evidence data suggesting a short-term mortality benefit of levosimendan compared with dobutamine, at present there are no robust and convincing data to support a distinct inotropic or vasodilator drug-based therapy as a superior solution to reduce mortality in haemodynamically unstable people with cardiogenic shock or LCOS.Considering the limited evidence derived from the present data due to a generally high risk of bias and imprecision, it should be emphasised that there remains a great need for large, well-designed randomised trials on this topic to close the gap between daily practice in critical care medicine and the available evidence. It seems to be useful to apply the concept of 'early goal-directed therapy' in cardiogenic shock and LCOS with early haemodynamic stabilisation within predefined timelines. Future clinical trials should therefore investigate whether such a therapeutic concept would influence survival rates much more than looking for the 'best' drug for haemodynamic support.
[Mh] Termos MeSH primário: Baixo Débito Cardíaco/tratamento farmacológico
Cardiotônicos/uso terapêutico
Infarto do Miocárdio/complicações
Choque Cardiogênico/tratamento farmacológico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Baixo Débito Cardíaco/etiologia
Baixo Débito Cardíaco/mortalidade
Causas de Morte
Dobutamina/uso terapêutico
Enoximona/uso terapêutico
Seres Humanos
Hidrazonas/uso terapêutico
Meia-Idade
Infarto do Miocárdio/mortalidade
Óxido Nítrico/uso terapêutico
Piridazinas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Choque Cardiogênico/etiologia
Choque Cardiogênico/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Hydrazones); 0 (Pyridazines); 0 (Vasodilator Agents); 31C4KY9ESH (Nitric Oxide); 349552KRHK (simendan); 3S12J47372 (Dobutamine); C7Z4ITI7L7 (Enoximone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009669.pub3


  2 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770407
[Au] Autor:Li S; Fu S; Xiao Y; Xu G
[Ad] Endereço:Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
[Ti] Título:Recent Perioperative Pharmacological Prevention of Acute Kidney Injury after Cardiac Surgery: A Narrative Review.
[So] Source:Am J Cardiovasc Drugs;17(1):17-25, 2017 Feb.
[Is] ISSN:1179-187X
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Acute kidney injury (AKI) is a common and severe complication of cardiac surgery, and related rates of both hospitalization and long-term mortality are increasing. A number of studies have explored the preventive effects of perioperative pharmacological therapy on AKI after cardiac surgery. However, the mechanisms of AKI are multifaceted, and no universal treatment has been confirmed as beneficial. We review and analyze several current perioperative pharmacological therapies for AKI after cardiac surgery to identify promising preventive strategies.
[Mh] Termos MeSH primário: Lesão Renal Aguda/prevenção & controle
Procedimentos Cirúrgicos Cardíacos/efeitos adversos
Assistência Perioperatória/métodos
Complicações Pós-Operatórias/prevenção & controle
[Mh] Termos MeSH secundário: Lesão Renal Aguda/etiologia
Lesão Renal Aguda/metabolismo
Dexmedetomidina/uso terapêutico
Seres Humanos
Hidrazonas/uso terapêutico
Complicações Pós-Operatórias/etiologia
Complicações Pós-Operatórias/metabolismo
Piridazinas/uso terapêutico
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hydrazones); 0 (Pyridazines); 349552KRHK (simendan); 67VB76HONO (Dexmedetomidine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE
[do] DOI:10.1007/s40256-016-0194-z


  3 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173945
[Au] Autor:Pandit SS; Kulkarni MR; Pandit YB; Lad NP; Khedkar VM
[Ad] Endereço:Post Graduate and Research Centre, Department of Chemistry, Padmashri Vikhe Patil College of Arts, Science and Commerce, Pravaranagar, A/P Loni, Tal. Rahata, Dist. Ahmednagar, 413713, India. Electronic address: akankshapandit2002@yahoo.com.
[Ti] Título:Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF-α production.
[So] Source:Bioorg Med Chem Lett;28(1):24-30, 2018 01 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tumor necrosis factor-α is an important pro-inflammatory cytokine having a key role in hosts defensive process of immune systems and its over expression led to a diverse range of inflammatory diseases such as Rheumatoid arthritis, Cronh's disease, psoriasis, etc. This paper describes our medicinal chemistry efforts on imidazo[1,2-b]pyridazine scaffold: design, synthesis and biological evaluation. By the introducing sulfonamide functionality at 3 positions and substituting 6 positions with (hetero)-aryl groups', a small library of compounds was prepared. All synthesized compounds were screened for lipopolysaccharide (LPS) mediated TNF-α production inhibitory activity. Biological data revealed that the majority of the compounds of this series showed moderate to potent TNF-α production inhibitory activity. Compound 5u and 5v are the most potent compounds from the series with activity of IC = 0.5 µM and 0.3 µM respectively. A short SAR demonstrates that 3-sulfonyl-4-arylpiperidine-4-carbonitrile moiety on imidazo[1,2-b]pyridazine showed better activity compared to the 3-(4-aryllpiperazin-1-yl) sulfonyl) in hPBMC assay. The molecular modeling studies revealed that the potent TNF-α production inhibitory activity 5v due to the extra stability of complex because of an extra pi-pi (π-π) stacking, hydrogen-bonding interactions.
[Mh] Termos MeSH primário: Sulfonamidas/química
Fator de Necrose Tumoral alfa/metabolismo
[Mh] Termos MeSH secundário: Sítios de Ligação
Domínio Catalítico
Células Cultivadas
Desenho de Drogas
Seres Humanos
Ligações de Hidrogênio
Leucócitos Mononucleares/citologia
Leucócitos Mononucleares/efeitos dos fármacos
Leucócitos Mononucleares/metabolismo
Lipopolissacarídeos/toxicidade
Simulação de Acoplamento Molecular
Piridazinas/química
Relação Estrutura-Atividade
Sulfonamidas/síntese química
Sulfonamidas/farmacologia
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Lipopolysaccharides); 0 (Pyridazines); 0 (Sulfonamides); 0 (Tumor Necrosis Factor-alpha)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29229226
[Au] Autor:Murineddu G; Deligia F; Ragusa G; García-Toscano L; Gómez-Cañas M; Asproni B; Satta V; Cichero E; Pazos R; Fossa P; Loriga G; Fernández-Ruiz J; Pinna GA
[Ad] Endereço:Department of Chemistry and Pharmacy, University of Sassari, via F. Muroni 23/A, 07100 Sassari, Italy. Electronic address: muri@uniss.it.
[Ti] Título:Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB receptor ligand antagonists.
[So] Source:Bioorg Med Chem;26(1):295-307, 2018 01 01.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A series of sulfenamide and sulfonamide derivatives was synthesized and evaluated for the affinity at CB and CB receptors. The N-bornyl-S-(5,6-di-p-tolylpyridazin-3-yl)-sulfenamide, compound 11, displayed good affinity and high selectivity for CB receptors (K values of 44.6 nM for CB receptors and >40 µM for CB receptors, respectively). The N-isopinocampheyl-sulfenamide 12 and its sulfonamide analogue 22 showed similar selectivity for CB receptors with K values of 75.5 and 73.2 nM, respectively. These novel compounds behave as antagonists/inverse agonists at CB receptor in the [ S]-GTPγS binding assays, and none showed adequate predictive blood-brain barrier permeation, exhibiting low estimated LD . However, testing compound 12 in a supraspinal analgesic test (hot-plate) revealed that it was as effective as the classic CB receptor antagonist rimonabant, in reversing the analgesic effect of a cannabinoid agonist.
[Mh] Termos MeSH primário: Piridazinas/farmacologia
Receptor CB1 de Canabinoide/antagonistas & inibidores
Sulfamerazina/farmacologia
Sulfonamidas/farmacologia
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Seres Humanos
Ligantes
Simulação de Acoplamento Molecular
Estrutura Molecular
Piridazinas/química
Relação Estrutura-Atividade
Sulfamerazina/síntese química
Sulfamerazina/química
Sulfonamidas/síntese química
Sulfonamidas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Ligands); 0 (Pyridazines); 0 (Receptor, Cannabinoid, CB1); 0 (Sulfonamides); 0 (sulfenamide); UR1SAB295F (Sulfamerazine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180106
[Lr] Data última revisão:
180106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE


  5 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
[PMID]:27770771
[Au] Autor:Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
[Ad] Endereço:Cardiovascular, 1st Affiliated Hospital of Peking University, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China. huoyong@263.net.cn.
[Ti] Título:Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
[So] Source:BMC Cardiovasc Disord;16(1):201, 2016 10 22.
[Is] ISSN:1471-2261
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although several new drugs have been approved in recent years, pulmonary arterial hypertension (PAH) remains a rapidly progressive disease with a poor prognosis. Ambrisentan, a selective endothelin type A antagonist, has been approved for treatment of PAH. This open label study assessed the efficacy and safety of ambrisentan in Chinese subjects with PAH. METHODS: Eligible patients with PAH (World Health Organisation [WHO] functional class [FC] II orIII) were enrolled and received Ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week dose-adjustment period (dose titration to 10 mgallowed). Endpoints included: change from baseline in 6-Minute Walk Distance (6-MWD), N-Terminal Pro B-Type Natriuretic Peptide (NT-pro-BNP), WHO FC, Borg Dyspnoea Index (BDI), clinical worsening of PAH and incidences of adverse events (AE). RESULTS: One hundred thirty-three subjects (85 % women, mean age: 36 years) with PAH (WHOFC II or III) were enrolled and received ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week dose-adjustment period. Mean (SD) duration of drug exposure was 161.7 (27.13) days. Ambrisentan (average daily dose of 6.27 mg) significantly improved exercise capacity (6MWD) from baseline (mean: 377.1 m [m]) at week 12 (+53.6 m, p < 0.001) (primary endpoint). Improvement in exercise capacity was noted as early as week 4, and was sustained up to week 24 (+ 64.4 m, p < 0.001). NT-pro-BNP plasma levels decreased significantly (p < 0.001) at week 12 (-861.4 ng/L) and week 24 (-806 ng/L) from baseline (mean: 1600.7 ng/L). The WHO FC showed improvements for 44 subjects at week 12 and 51 subjects at week 24. BDI scores decreased significantly at week 12 (-0.3, p < 0.001) and week 24 (-0.2, p = 0.003) from baseline (mean: 2.5). Four patients died during the study (sudden cardiac death [n = 2], cerebral haemorrhage [n = 1], cardiac failure [n = 1]). Drug related adverse events occurred in 34.3 % of subjects; peripheral oedema (11.2 %) and flushing (8.2 %) occurred most frequently. CONCLUSION: Ambrisentan (5 and 10 mg, orally) significantly improved the exercise capacity in Chinese PAH subjects with a safety profile similar to that observed in global studies. TRIAL REGISTRATION: NCT No. (ClinicalTrials.gov): NCT01808313 ; Registration date (first time): February 28, 2013.
[Mh] Termos MeSH primário: Tolerância ao Exercício/efeitos dos fármacos
Hipertensão Pulmonar/tratamento farmacológico
Fenilpropionatos/administração & dosagem
Piridazinas/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Idoso
Anti-Hipertensivos/administração & dosagem
China/epidemiologia
Relação Dose-Resposta a Droga
Teste de Esforço
Feminino
Seguimentos
Seres Humanos
Hipertensão Pulmonar/epidemiologia
Hipertensão Pulmonar/fisiopatologia
Masculino
Meia-Idade
Morbidade/tendências
Estudos Prospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Phenylpropionates); 0 (Pyridazines); HW6NV07QEC (ambrisentan)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  6 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29176862
[Au] Autor:Koschmieder J; Fehling-Kaschek M; Schaub P; Ghisla S; Brausemann A; Timmer J; Beyer P
[Ad] Endereço:University of Freiburg, Faculty of Biology, Freiburg, Germany.
[Ti] Título:Plant-type phytoene desaturase: Functional evaluation of structural implications.
[So] Source:PLoS One;12(11):e0187628, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Phytoene desaturase (PDS) is an essential plant carotenoid biosynthetic enzyme and a prominent target of certain inhibitors, such as norflurazon, acting as bleaching herbicides. PDS catalyzes the introduction of two double bonds into 15-cis-phytoene, yielding 9,15,9'-tri-cis-ζ-carotene via the intermediate 9,15-di-cis-phytofluene. We present the necessary data to scrutinize functional implications inferred from the recently resolved crystal structure of Oryza sativa PDS in a complex with norflurazon. Using dynamic mathematical modeling of reaction time courses, we support the relevance of homotetrameric assembly of the enzyme observed in crystallo by providing evidence for substrate channeling of the intermediate phytofluene between individual subunits at membrane surfaces. Kinetic investigations are compatible with an ordered ping-pong bi-bi kinetic mechanism in which the carotene and the quinone electron acceptor successively occupy the same catalytic site. The mutagenesis of a conserved arginine that forms a hydrogen bond with norflurazon, the latter competing with plastoquinone, corroborates the possibility of engineering herbicide resistance, however, at the expense of diminished catalytic activity. This mutagenesis also supports a "flavin only" mechanism of carotene desaturation not requiring charged residues in the active site. Evidence for the role of the central 15-cis double bond of phytoene in determining regio-specificity of carotene desaturation is presented.
[Mh] Termos MeSH primário: Oryza/enzimologia
Oxirredutases/química
Oxirredutases/metabolismo
[Mh] Termos MeSH secundário: Biocatálise/efeitos dos fármacos
Carotenoides/química
Carotenoides/metabolismo
Cromatografia Líquida
Simulação por Computador
Ensaios Enzimáticos
Cinética
Espectrometria de Massas
Modelos Moleculares
Mutação/genética
Oxirredutases/antagonistas & inibidores
Multimerização Proteica
Piridazinas/farmacologia
Estereoisomerismo
Especificidade por Substrato
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pyridazines); 36-88-4 (Carotenoids); 87E4NJ6N51 ((all-E) phytoene); EC 1.- (Oxidoreductases); EC 1.14.99.- (phytoene dehydrogenase); KES1HB07E4 (norflurazone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0187628


  7 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460361
[Au] Autor:Zivkovic MD; Rajkovic S; Glisic BD; Draskovic NS; Djuran MI
[Ad] Endereço:University of Kragujevac, Faculty of Science, Department of Chemistry, Radoja Domanovica 12, 34000 Kragujevac, Serbia. Electronic address: mzivkovic@kg.ac.rs.
[Ti] Título:Hydrolysis of the amide bond in histidine- and methionine-containing dipeptides promoted by pyrazine and pyridazine palladium(II)-aqua dimers: Comparative study with platinum(II) analogues.
[So] Source:Bioorg Chem;72:190-198, 2017 06.
[Is] ISSN:1090-2120
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Two dinuclear palladium(II) complexes, [{Pd(en)Cl} (µ-pz)](NO ) and [{Pd(en)Cl} (µ-pydz)](NO ) , have been synthesized and characterized by elemental microanalysis and spectroscopic ( H and C NMR, IR and UV-vis) techniques (en is ethylenediamine; pz is pyrazine and pydz is pyridazine). The square planar geometry of palladium(II) metal centers in these complexes has been predicted by DFT calculations. The chlorido complexes were converted into the corresponding aqua complexes, [{Pd(en)(H O)} (µ-pz)] and [{Pd(en)(H O)} (µ-pydz)] , and their reactions with N-acetylated l-histidylglycine (Ac-l-His-Gly) and l-methionylglycine (Ac-l-Met-Gly) were studied by H NMR spectroscopy. The palladium(II)-aqua complexes and dipeptides were reacted in 1:1 M ratio, and all reactions performed in the pH range 2.0
[Mh] Termos MeSH primário: Amidas/química
Dipeptídeos/química
Histidina/química
Metionina/química
Compostos Organometálicos/química
[Mh] Termos MeSH secundário: Dimerização
Relação Dose-Resposta a Droga
Hidrólise
Estrutura Molecular
Paládio/química
Platina/química
Pirazinas/química
Piridazinas/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amides); 0 (Dipeptides); 0 (Organometallic Compounds); 0 (Pyrazines); 0 (Pyridazines); 49DFR088MY (Platinum); 4QD397987E (Histidine); 5TWQ1V240M (Palladium); AE28F7PNPL (Methionine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  8 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29120128
[Au] Autor:Mehta RH; Alexander JH; LEVO-CTS Steering Committee Members and Trial Investigators
[Ad] Endereço:Duke Clinical Research Institute, Durham, NC
[Ti] Título:Levosimendan in Cardiac Surgery.
[So] Source:N Engl J Med;377(19):1900-1, 2017 11 09.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hidrazonas
Piridazinas
[Mh] Termos MeSH secundário: Procedimentos Cirúrgicos Cardíacos
Cardiotônicos
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Hydrazones); 0 (Pyridazines); 349552KRHK (simendan)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171110
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1711938


  9 / 6136 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29120127
[Au] Autor:Putzu A; Clivio S; Cassina T
[Ad] Endereço:Cardiocentro Ticino, Lugano, Switzerland
[Ti] Título:Levosimendan in Cardiac Surgery.
[So] Source:N Engl J Med;377(19):1899-1900, 2017 11 09.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hidrazonas
Piridazinas
[Mh] Termos MeSH secundário: Procedimentos Cirúrgicos Cardíacos
Cardiotônicos
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Hydrazones); 0 (Pyridazines); 349552KRHK (simendan)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171110
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1711938


  10 / 6136 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29120124
[Au] Autor:Dell'Anna AM; De Pascale G; Antonelli M
[Ad] Endereço:A. Gemelli School of Medicine, Rome, Italy anthosdel@yahoo.it
[Ti] Título:Levosimendan in Cardiac Surgery.
[So] Source:N Engl J Med;377(19):1899, 2017 11 09.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hidrazonas
Piridazinas
[Mh] Termos MeSH secundário: Procedimentos Cirúrgicos Cardíacos
Cardiotônicos
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Hydrazones); 0 (Pyridazines); 349552KRHK (simendan)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171110
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1711938



página 1 de 614 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde